Palbociclib Plus Fulvestrant Maintains Long-Term Overall Survival Benefit in HR+/HER2– Advanced Breast Cancer
Open Access
- 21 June 2021
- journal article
- editorial
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 26 (S3) , S5-S6
Abstract
With more than 6 years of follow-up in the phase III PALOMA-3 trial, the addition of palbociclib to fulvestrant maintained a significant survival benefit compared with fulvestrant alone in patients with HR-positive, HER2-negative advanced breast cancer that progressed on prior endocrine therapy.Keywords
This publication has 4 references indexed in Scilit:
- Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.Journal of Clinical Oncology, 2021
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast CancerNew England Journal of Medicine, 2018
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialThe Lancet Oncology, 2016
- Palbociclib in Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2015